JP2008510783A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008510783A5 JP2008510783A5 JP2007528985A JP2007528985A JP2008510783A5 JP 2008510783 A5 JP2008510783 A5 JP 2008510783A5 JP 2007528985 A JP2007528985 A JP 2007528985A JP 2007528985 A JP2007528985 A JP 2007528985A JP 2008510783 A5 JP2008510783 A5 JP 2008510783A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- group
- compound according
- cancer
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 15
- 125000003118 aryl group Chemical group 0.000 claims 9
- 125000000217 alkyl group Chemical group 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 125000002252 acyl group Chemical group 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 150000001408 amides Chemical class 0.000 claims 5
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 108700020463 BRCA1 Proteins 0.000 claims 3
- 102000036365 BRCA1 Human genes 0.000 claims 3
- 101150072950 BRCA1 gene Proteins 0.000 claims 3
- 108700020462 BRCA2 Proteins 0.000 claims 3
- 102000052609 BRCA2 Human genes 0.000 claims 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 3
- 101150008921 Brca2 gene Proteins 0.000 claims 3
- 108020004414 DNA Proteins 0.000 claims 3
- 230000002950 deficient Effects 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 230000005865 ionizing radiation Effects 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 230000037361 pathway Effects 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 125000001391 thioamide group Chemical group 0.000 claims 2
- 125000005730 thiophenylene group Chemical group 0.000 claims 2
- SRNWOUGRCWSEMX-KEOHHSTQSA-N ADP-beta-D-ribose Chemical group C([C@H]1O[C@H]([C@@H]([C@@H]1O)O)N1C=2N=CN=C(C=2N=C1)N)OP(O)(=O)OP(O)(=O)OC[C@H]1O[C@@H](O)[C@H](O)[C@@H]1O SRNWOUGRCWSEMX-KEOHHSTQSA-N 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 208000032456 Hemorrhagic Shock Diseases 0.000 claims 1
- 206010029350 Neurotoxicity Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 108010064218 Poly (ADP-Ribose) Polymerase-1 Proteins 0.000 claims 1
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 claims 1
- 102100023652 Poly [ADP-ribose] polymerase 2 Human genes 0.000 claims 1
- 101710144590 Poly [ADP-ribose] polymerase 2 Proteins 0.000 claims 1
- 108091026813 Poly(ADPribose) Proteins 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 206010049771 Shock haemorrhagic Diseases 0.000 claims 1
- 206010044221 Toxic encephalopathy Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 230000001668 ameliorated effect Effects 0.000 claims 1
- 125000003368 amide group Chemical group 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 150000001721 carbon Chemical group 0.000 claims 1
- 238000013130 cardiovascular surgery Methods 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 230000003013 cytotoxicity Effects 0.000 claims 1
- 231100000135 cytotoxicity Toxicity 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 125000004185 ester group Chemical group 0.000 claims 1
- AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 claims 1
- -1 hydroxy, amino Chemical group 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 208000037906 ischaemic injury Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000007135 neurotoxicity Effects 0.000 claims 1
- 231100000228 neurotoxicity Toxicity 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 238000011275 oncology therapy Methods 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 125000005551 pyridylene group Chemical group 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000009291 secondary effect Effects 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0419072.4A GB0419072D0 (en) | 2004-08-26 | 2004-08-26 | Phthalazinone derivatives |
| US60495604P | 2004-08-27 | 2004-08-27 | |
| PCT/GB2005/003343 WO2006021801A1 (en) | 2004-08-26 | 2005-08-26 | 4-heteroarylmethyl substituted phthalazinone derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008510783A JP2008510783A (ja) | 2008-04-10 |
| JP2008510783A5 true JP2008510783A5 (https=) | 2008-09-04 |
Family
ID=35219560
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007528985A Pending JP2008510783A (ja) | 2004-08-26 | 2005-08-26 | ４−ヘテロアリールメチル置換フタラジノン誘導体 |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP1791827A1 (https=) |
| JP (1) | JP2008510783A (https=) |
| KR (1) | KR20070057859A (https=) |
| AU (1) | AU2005276229A1 (https=) |
| BR (1) | BRPI0514632A (https=) |
| CA (1) | CA2577191A1 (https=) |
| IL (1) | IL181408A0 (https=) |
| MX (1) | MX2007002318A (https=) |
| NO (1) | NO20071579L (https=) |
| NZ (1) | NZ553979A (https=) |
| WO (1) | WO2006021801A1 (https=) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0521373D0 (en) * | 2005-10-20 | 2005-11-30 | Kudos Pharm Ltd | Pthalazinone derivatives |
| GB0610680D0 (en) | 2006-05-31 | 2006-07-12 | Istituto Di Ricerche D Biolog | Therapeutic compounds |
| WO2007138355A1 (en) | 2006-05-31 | 2007-12-06 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Pyrrolo[1,2-a]pyrazin-1(2h)-one and pyrrolo[1,2-d][1,2,4]triazin-1(2h)-one derivatives as inhibitors of poly(adp-ribose)polymerase(parp) |
| JP4611444B2 (ja) | 2007-01-10 | 2011-01-12 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤としてのアミド置換インダゾール |
| JP5603770B2 (ja) | 2007-05-31 | 2014-10-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｃｒ２受容体拮抗薬およびその使用 |
| GB0716532D0 (en) * | 2007-08-24 | 2007-10-03 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| MX2010002749A (es) * | 2007-09-14 | 2010-06-25 | Astrazeneca Ab | Derivados de ftalazinona. |
| EP2220073B1 (en) | 2007-11-15 | 2014-09-03 | MSD Italia S.r.l. | Pyridazinone derivatives as parp inhibitors |
| UY31603A1 (es) * | 2008-01-23 | 2009-08-31 | Derivados de ftalazinona | |
| GB0804755D0 (en) | 2008-03-14 | 2008-04-16 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| CN102256963B (zh) | 2008-12-19 | 2014-06-11 | 贝林格尔.英格海姆国际有限公司 | 作为ccr2受体拮抗剂用于治疗炎症、哮喘和copd的环状嘧啶-4-甲酰胺 |
| ES2674275T3 (es) | 2009-12-17 | 2018-06-28 | Centrexion Therapeutics Corporation | Antagonistas del receptor CCR2 y usos de los mismos |
| WO2011141474A1 (en) | 2010-05-12 | 2011-11-17 | Boehringer Ingelheim International Gmbh | Novel ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments |
| JP5646736B2 (ja) | 2010-05-12 | 2014-12-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規ｃｃｒ２受容体アンタゴニスト、これらの製造方法、及び薬物としてのこれらの使用 |
| WO2011144501A1 (en) | 2010-05-17 | 2011-11-24 | Boehringer Ingelheim International Gmbh | Ccr2 antagonists and uses thereof |
| WO2011147772A1 (en) | 2010-05-25 | 2011-12-01 | Boehringer Ingelheim International Gmbh | Ccr2 receptor antagonists |
| US8962656B2 (en) | 2010-06-01 | 2015-02-24 | Boehringer Ingelheim International Gmbh | CCR2 antagonists |
| JP2013532683A (ja) | 2010-07-27 | 2013-08-19 | カディラ ヘルスケア リミティド | ポリ（ａｄｐリボース）ポリメラーゼ−１阻害剤としての、置換４−（４−フルオロ−３−（ピペラジン−１−カルボニル）ベンジル）フタラジン−１（２ｈ）−オン誘導体 |
| CN102372716A (zh) | 2010-08-09 | 2012-03-14 | 江苏恒瑞医药股份有限公司 | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 |
| KR101242572B1 (ko) * | 2010-10-12 | 2013-03-19 | 한국화학연구원 | 5-환 헤테로 아릴로 치환된 프탈라지논 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 약학적 조성물 |
| JP5699223B2 (ja) * | 2010-12-02 | 2015-04-08 | シャンハイ デュァ ノボ ファルマテック カンパニー リミテッド | 複素環誘導体、その合成法および医療用途 |
| CA2829123C (en) * | 2011-03-14 | 2016-04-12 | Eternity Bioscience Inc. | Quinazolinediones and their use |
| TWI577693B (zh) * | 2011-05-31 | 2017-04-11 | 江蘇康緣藥業股份有限公司 | 聚（ａｄｐ-核糖）聚合酶之三環抑制劑 |
| EP2731941B1 (en) | 2011-07-15 | 2019-05-08 | Boehringer Ingelheim International GmbH | Novel and selective ccr2 antagonists |
| CN103130723B (zh) | 2011-11-30 | 2015-01-14 | 成都地奥制药集团有限公司 | 一种多聚(adp-核糖)聚合酶抑制剂 |
| CN102964354B (zh) * | 2012-11-16 | 2014-08-13 | 江苏先声药业有限公司 | 一类噻吩并咪唑衍生物及其应用 |
| CN102977040B (zh) * | 2012-11-20 | 2015-06-03 | 浙江工业大学 | 一种2-喹喔啉基二甲缩醛和2-喹喔啉基甲醛的合成方法 |
| HUE030613T2 (en) | 2012-12-31 | 2017-05-29 | Cadila Healthcare Ltd | Substituted phthalazin-1 (2H) -one derivatives as selective inhibitors of poly (ADP-ribose) polymerase-1 |
| ES2753386T3 (es) | 2013-03-13 | 2020-04-08 | Forma Therapeutics Inc | Derivados de 2-hidroxi-1-{4-[(4-fenil)fenil]carbonil}piperazin-1-il}etano-1-ona y compuestos relacionados como inhibidores de sintasa de ácido graso (FASN) para el tratamiento del cáncer |
| CN106146492A (zh) * | 2015-04-17 | 2016-11-23 | 上海汇伦生命科技有限公司 | 杂环并咪唑类化合物、其药物组合物及其制备方法和用途 |
| PT3317270T (pt) | 2015-07-02 | 2020-08-24 | Centrexion Therapeutics Corp | (4-((3r,4r)-3-metoxitetrahidro-pirano-4-ilamino)piperidina-1-il)(5-metil-6-(((2r,6s)-6-(p-tolil)tetrahidro-2h-pirano-2-il)metilamino)pirimidina-4-il)citrato de metanona |
| CN105384684B (zh) * | 2015-12-16 | 2018-02-13 | 辽宁工程技术大学 | 一种2‑氰基‑6‑甲基吡啶的制备方法 |
| EP3758695A4 (en) * | 2018-02-28 | 2021-10-06 | The Trustees Of The University Of Pennsylvania | POLY (AD-RIBOSE) -POLYMERASE 1 DEPENDENT CYTOTOXIC AGENTS WITH LOW AFFINITY |
| TWI767148B (zh) | 2018-10-10 | 2022-06-11 | 美商弗瑪治療公司 | 抑制脂肪酸合成酶(fasn) |
| US10793554B2 (en) | 2018-10-29 | 2020-10-06 | Forma Therapeutics, Inc. | Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone |
| US20220110936A1 (en) * | 2019-02-02 | 2022-04-14 | Shanghai Institute Of Organic Chemistry, Chinese Academy Of Sciences | Pharmaceutical composition for treatment of neurodegenerative diseases or diseases caused by abnormality of rna binding protein and applications thereof |
| SI3999506T1 (sl) | 2019-07-19 | 2025-06-30 | Astrazeneca Ab | Zaviralci PARP1 |
| US20230234938A1 (en) | 2020-04-28 | 2023-07-27 | Rhizen Pharmaceuticals Ag | Novel compounds useful as poly(adp-ribose) polymerase (parp) inhibitors |
| WO2022090938A1 (en) | 2020-10-31 | 2022-05-05 | Rhizen Pharmaceuticals Ag | Phthalazinone derivatives useful as parp inhibitors |
| CA3214298A1 (en) | 2021-04-08 | 2022-10-13 | Swaroop Kumar Venkata Satya VAKKALANKA | Inhibitors of poly(adp-ribose) polymerase |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA882639B (en) * | 1987-05-02 | 1988-09-30 | Asta-Pharma Aktiengesellschaft | New 2-aminoalkyl-4-benzyl-1(2h)-phthalazinone derivatives |
| DE3813531A1 (de) * | 1987-05-02 | 1988-11-10 | Asta Pharma Ag | Neue 2-aminoalkyl-4-benzyl-1-(2h)-phthalazinon-derivate |
| CA2205757C (en) * | 1996-05-30 | 2006-01-24 | F. Hoffmann-La Roche Ag | Pyridazinone derivatives and their use as inhibitors of prostaglandin g/h synthase i and ii(cox i and ii) |
| GB0026505D0 (en) * | 2000-10-30 | 2000-12-13 | Kudos Pharm Ltd | Phthalazinone derivatives |
| HU228960B1 (hu) * | 2000-10-30 | 2013-07-29 | Kudos Pharm Ltd | Ftalazinon-származékok |
| WO2002090334A1 (en) * | 2001-05-08 | 2002-11-14 | Kudos Pharmaceuticals Limited | Isoquinolinone derivatives as parp inhibitors |
| AU2003211381B9 (en) * | 2002-02-19 | 2009-07-30 | Ono Pharmaceutical Co., Ltd. | Fused pyridazine derivative compounds and drugs containing the compounds as the active ingredient |
| DE60335359D1 (de) * | 2002-04-30 | 2011-01-27 | Kudos Pharm Ltd | Phthalazinonderivate |
| PL1633724T3 (pl) * | 2003-03-12 | 2011-10-31 | Kudos Pharm Ltd | Pochodne ftalazynonu |
-
2005
- 2005-08-26 JP JP2007528985A patent/JP2008510783A/ja active Pending
- 2005-08-26 WO PCT/GB2005/003343 patent/WO2006021801A1/en not_active Ceased
- 2005-08-26 CA CA002577191A patent/CA2577191A1/en not_active Abandoned
- 2005-08-26 BR BRPI0514632-1A patent/BRPI0514632A/pt not_active IP Right Cessation
- 2005-08-26 AU AU2005276229A patent/AU2005276229A1/en not_active Abandoned
- 2005-08-26 EP EP05775527A patent/EP1791827A1/en not_active Withdrawn
- 2005-08-26 KR KR1020077006778A patent/KR20070057859A/ko not_active Ceased
- 2005-08-26 NZ NZ553979A patent/NZ553979A/en not_active IP Right Cessation
- 2005-08-26 MX MX2007002318A patent/MX2007002318A/es active IP Right Grant
-
2007
- 2007-02-18 IL IL181408A patent/IL181408A0/en unknown
- 2007-03-26 NO NO20071579A patent/NO20071579L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008510783A5 (https=) | ||
| JP2006519827A5 (https=) | ||
| JP2008001718A5 (https=) | ||
| JP2011510056A5 (https=) | ||
| US6218418B1 (en) | 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents | |
| CN108570059B (zh) | 一种具有prmt5抑制活性的化合物及其制备和应用 | |
| JP2008535902A5 (https=) | ||
| CA2517629A1 (en) | Phthalazinone derivatives | |
| JP2006509719A5 (https=) | ||
| JP2009515980A5 (https=) | ||
| JP2008535903A5 (https=) | ||
| PT1797099E (pt) | Compostos de piperidinilamino-tieno[2,3-d]pirimidina | |
| KR20140043900A (ko) | Ape1 매개된 질환을 치료하기 위한 퀴논 화합물 | |
| US11981682B2 (en) | Substituted cyclopenta[c]pyrroles as ABHD6 antagonists | |
| GB2265372A (en) | Pyrrolo-pyridazinone derivatives and pharmaceutical uses thereof | |
| US7592353B2 (en) | Substituted 3-amino-thieno[2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses | |
| KR20190040763A (ko) | 피라졸로피리딘 유도체 화합물 및 이의 용도 | |
| US20220033388A1 (en) | HDAC1,2 Inhibitors | |
| Sharma et al. | Synthesis, evaluation and molecular docking of thiazolopyrimidine derivatives as dipeptidyl peptidase iv inhibitors | |
| KR101464591B1 (ko) | 5, 6, 또는 7-치환-3-(헤테로)아릴이소퀴놀린아민 유도체 및 그 치료 용도 | |
| KR20130118612A (ko) | 신규한 아미노피리딘 유도체 및 이의 용도 | |
| KR100916160B1 (ko) | 약제학적 항암 조성물 | |
| CA2634165A1 (en) | Pyrrolo [1,2-a]quinoxaline derivatives as adenosine a3 receptor modulators and uses thereof | |
| JP2005533038A5 (https=) | ||
| CN103435562B (zh) | 6-取代苯并二氮卓-2,4-二酮类化合物及其用途 |